Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure

European Journal of Internal Medicine

Volumn 25, Issue 1, 2014, Pages 67-72

  Ferreira, João Pedro ^a   Santos, Mário ^a   Almeida, Sofia ^b   Marques, Irene ^a   Bettencourt, Paulo ^c   Carvalho, Henrique ^a  

^a Centro Hospitalar Universitario do Porto   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c Centro Hospitalar Universitário de São João   (Portugal)

Author keywords

Acute heart failure; Mineralocorticoid receptor antagonism; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NITRATE; POTASSIUM; SODIUM; SPIRONOLACTONE; UREA;

ACUTE HEART FAILURE; AGED; ALBUMINURIA; ARTICLE; CENTRAL VENOUS PRESSURE; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CRACKLE; DRUG EFFECT; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; HEART EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; SINGLE BLIND PROCEDURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ACUTE HEART FAILURE; MINERALOCORTICOID RECEPTOR ANTAGONISM; NATRIURETIC PEPTIDES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DISEASE PROGRESSION; DIURETICS; EDEMA; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POTASSIUM; PULMONARY EDEMA; RENAL INSUFFICIENCY; SINGLE-BLIND METHOD; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84892811303     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.08.711     Document Type: Article

References (30)

1. D.L. Mann, and M.R. Bristow Mechanisms and models in heart failure: the biomechanical model and beyond Circulation 2005 2837 2849 [United States]
2. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker et al. a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 1309 1321 [United States: 2003 Massachusetts Medical Society]
3. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
4. M. Gheorghiade, and P.S. Pang Acute heart failure syndromes J Am Coll Cardiol 2009 557 573 [United States]
5. M. Albaghdadi, M. Gheorghiade, and B. Pitt Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes Eur Heart J 2011 2626 2633 [England]
6. D. Aronson, and A.J. Burger Neurohormonal prediction of mortality following admission for decompensated heart failure Am J Cardiol 2003 245 248 [United States]
7. B.M. Schmidt, U. Sammer, I. Fleischmann, M. Schlaich, C. Delles, and R.E. Schmieder Rapid nongenomic effects of aldosterone on the renal vasculature in humans Hypertension 2006 650 655 [United States]
8. C.A. Farquharson, and A.D. Struthers Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy Clin Sci (Lond) 103 2002 425 431
9. L. De Luca, G.C. Fonarow, K.F. Adams Jr., A. Mebazaa, L. Tavazzi, and K. Swedberg et al. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy Heart Fail Rev 12 2007 97 104
10. A.D. Struthers Aldosterone: cardiovascular assault Am Heart J 2002 S2 S7 [United States]
11. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
12. G.C. Fonarow, K.F. Adams Jr., W.T. Abraham, C.W. Yancy, and W.J. Boscardin Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis JAMA 2005 572 580 [United States]
13. D.S. Lee, P.C. Austin, J.L. Rouleau, P.P. Liu, D. Naimark, and J.V. Tu Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model JAMA 2003 2581 2587 [United States]
14. A.A. van Vliet, A.J. Donker, J.J. Nauta, and F.W. Verheugt Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor Am J Cardiol 71 1993 21A 28A
15. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, and R. Mukherjee Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (ephesus) Circulation 2008 1643 1650 [United States]
16. G.M. Felker, K.L. Lee, D.A. Bull, M.M. Redfield, L.W. Stevenson, and S.R. Goldsmith et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797 805
17. J. Butler, D.E. Forman, W.T. Abraham, S.S. Gottlieb, E. Loh, and B.M. Massie et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients Am Heart J 2004 331 338 [United States]
18. R.W. Schrier Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006 1 8 [United States]
19. S. Sanjay, R.A. Annigeri, R. Seshadri, B.S. Rao, K.C. Prakash, and M.K. Mani The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease Nephrology (Carlton) 2008 247 250 [Australia]
20. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N Engl J Med 341 1999 709 717
21. A. Ahmed, F. Zannad, T.E. Love, J. Tallaj, M. Gheorghiade, and O.J. Ekundayo et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure Eur Heart J 2007 1334 1343 [England]
22. P.L. Selvais, A. Robert, S. Ahn, F. van Linden, J.M. Ketelslegers, and H. Pouleur et al. Direct comparison between endothelin-1, n-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure J Card Fail 2000 201 207 [United States]
23. C. Hall, J.L. Rouleau, L. Moye, J. de Champlain, D. Bichet, and M. Klein et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction Circulation 89 1994 1934 1942
24. T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, and T. Tsutsui et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 2001 1228 1233 [United States]
25. M. Metra, S. Nodari, G. Parrinello, C. Specchia, L. Brentana, and P. Rocca et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of nt-probnp and cardiac troponin-t Eur J Heart Fail 2007 776 786 [Netherlands]
26. P. Bettencourt, A. Azevedo, J. Pimenta, F. Frioes, S. Ferreira, and A. Ferreira N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circulation 2004 2168 2174 [United States]
27. M. Gekle, and C. Grossmann Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458 2009 231 246
28. A.M. Marney, and N.J. Brown Aldosterone and end-organ damage Clin Sci (Lond) 2007 267 278 [England]
29. J. Hensen, W.T. Abraham, J.A. Durr, and R.W. Schrier Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention Am J Nephrol 11 1991 441 446
30. R.J. Eudy, V. Sahasrabudhe, K. Sweeney, M. Tugnait, A. King-Ahmad, and K. Near et al. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism J Transl Med 2011 180 [England]